Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b
Jean-Jacques Kiladjian, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva, Miklós Egyed, Petr Ďulíček, Árpád Illés, Halyna Pylypenko, Lylia Sivcheva, Jiřı́ Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans Carl Hasselbalch, Róbert Královics, Heinz Gisslinger, the PROUD-PV Study Group, Jean-Jacques Kiladjian, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva, Miklós Egyed, Petr Dulicek, Árpád Illés, Halyna Pylypenko, Lylia Sivcheva, Jiřı́ Mayer, Vera Yablokova, Heinz Gisslinger
Abstract
Interferon alfa not only restores normal blood cell counts in patients with polycythemia vera (PV) but can diminish the mutant JAK2V617F allele burden After discontinuing long-term interferon therapy, hematologic responses may persist Allele burden declines gradually during interferon treatment